Immix Biopharma publishes corporate presentation on NXC-201 BCMA CAR-T in relapsed/refractory AL amyloidosis
IMMX•Development and commercialization timeline
The company outlined a planned BLA submission following 1-year follow-up for all 45 patients; the next trial update is targeted for late September 2026.
The commercial launch plan targets the end of 2027, and the presentation cited USD 588,000 as the 2026 price reference for Carvykti BCMA CAR-T.
NEXICART-2 trial enrollment and response data
NEXICART-2, a U.S. open-label single-arm phase 1/2 trial, completed enrollment at 45 patients; the primary efficacy measure is complete hematologic response.
The presentation cited a 95% complete response rate for NXC-201, versus 0-10% complete response rates reported for investigator’s-choice regimens.
Corporate presentation highlights NXC-201 program
Immix highlighted NXC-201, a BCMA-targeted CAR-T, as its lead program for relapsed or refractory AL amyloidosis.
